Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran

Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC ( Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas )

Key insights from head and neck research at ASCO 2025

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA

Key insights from head and neck research at ASCO 2025 ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC ( Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

Ordronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2...

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy

Ordronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory...

Dr Anthony Stein - City of Hope, Duarte, USA

$Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia ( Dr Anthony Stein - City of Hope, Duarte, USA )$

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with...

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM ( Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France )

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared...

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies ( Dr Moritz Fürstenau - University of Cologne, Cologne, Germany )

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy...

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

More from ecancer